Darwin J Prockop
Overview
Explore the profile of Darwin J Prockop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
13563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mittal M, Tiruppathi C, Nepal S, Zhao Y, Grzych D, Soni D, et al.
Proc Natl Acad Sci U S A
. 2016 Dec;
113(50):E8151-E8158.
PMID: 27911817
TNFα-stimulated gene-6 (TSG6), a 30-kDa protein generated by activated macrophages, modulates inflammation; however, its mechanism of action and role in the activation of macrophages are not fully understood. Here we...
12.
Yun Y, Park S, Lee H, Ko J, Kim M, Wee W, et al.
Cytotherapy
. 2016 Nov;
19(1):28-35.
PMID: 27840134
Background Aims: Mesenchymal stromal cells (MSCs) offer tremendous potential for therapeutic applications for inflammatory diseases. However, tissue-derived MSCs, such as bone marrow-derived MSCs (BM-MSCs), have considerable donor variations and limited...
13.
Prockop D
Cytotherapy
. 2016 Oct;
19(1):1-8.
PMID: 27769637
From the outset, it was apparent that developing new therapies with mesenchymal stem/stromal cells (MSCs) was not a simple or easy task. Among the earliest experiments was administration of MSCs...
14.
Bartosh T, Ullah M, Zeitouni S, Beaver J, Prockop D
Proc Natl Acad Sci U S A
. 2016 Oct;
113(42):E6447-E6456.
PMID: 27698134
Patients with breast cancer often develop malignant regrowth of residual drug-resistant dormant tumor cells years after primary treatment, a process defined as cancer relapse. Deciphering the causal basis of tumor...
15.
Mohammadipoor A, Lee R, Prockop D, Bartosh T
Transl Res
. 2016 Jul;
177:127-142.
PMID: 27469269
Stanniocalcin-1 (STC-1) is a multifunctional glycoprotein with antioxidant and anti-inflammatory properties. Ischemic myocardial necrosis generates "danger" signals that perpetuate detrimental inflammatory reactions often involving monocyte recruitment and their subsequent differentiation...
16.
Bazhanov N, Ylostalo J, Bartosh T, Tiblow A, Mohammadipoor A, Foskett A, et al.
Stem Cell Res Ther
. 2016 Feb;
7:27.
PMID: 26864573
Background: Mesenchymal stem/progenitor cells (MSC) have shown beneficial effects in many models of disease in part by modulating excessive inflammatory and immune responses. Frequently the beneficial effects of MSC persist...
17.
Prockop D
Matrix Biol
. 2016 Jan;
51:7-13.
PMID: 26807758
Fibrosis and scarring are the end stage of many disease processes. In effect, the collagen fibers that initially provide a necessary strength during the repair of injured tissues are frequently...
18.
Kim D, Choi H, Nishida H, Oh J, Gregory C, Lee R, et al.
PLoS One
. 2016 Jan;
11(1):e0147553.
PMID: 26793973
TNF-α stimulated gene/protein 6 (TNFAIP6/TSG-6) is a multifunctional protein that has a number of potential therapeutic applications. Experiments and clinical trials with TSG-6, however, have been limited by the technical...
19.
Kim D, Nishida H, An S, Shetty A, Bartosh T, Prockop D
Proc Natl Acad Sci U S A
. 2015 Dec;
113(1):170-5.
PMID: 26699510
Extracellular vesicles (EVs) secreted by cells present an attractive strategy for developing new therapies, but progress in the field is limited by several issues: The quality of the EVs varies...
20.
Ko J, Lee H, Jeong H, Kim M, Wee W, Yoon S, et al.
Proc Natl Acad Sci U S A
. 2015 Dec;
113(1):158-63.
PMID: 26699483
Intravenously administered mesenchymal stem/stromal cells (MSCs) engraft only transiently in recipients, but confer long-term therapeutic benefits in patients with immune disorders. This suggests that MSCs induce immune tolerance by long-lasting...